Halozyme Therapeutics Inc

NASDAQ:HALOUnited States

Today

Show headlines and story abstract

• DJ Halozyme Therapeutics Down Over 13%, on Pace for Largest Percent Decrease Since January 2016 -- Data Talk, from 23 minutes ago by Dow Jones

  23 minutes ago by Dow Jones
  Companies Mentioned: HALO
  
  Halozyme Therapeutics, Inc. (HALO) is currently at $46.88, down $7.08 or 13.12%
  
  --Would be lowest close since June 5, 2024, when it closed at $45.65
  
  --On pace for largest percent decrease since Jan. 13, 2016, when it fell 17.68%
  

• Halozyme Submits $2.11 Billion Acquisition Offer For Evotec, from 5 hours ago by MT Newswires

  5 hours ago by MT Newswires
  Companies Mentioned: HALO, EVO
  06:31 AM EST, 11/15/2024 (MT Newswires) -- Halozyme Therapeutics (HALO) offered to acquire German drug maker Evotec (EVO) in a deal with an equity value of 2 billion euros ($2.11 billion). Halozyme submitted a non-binding proposal to Evotec's manage...

• DJ Evotec Shares Surge on $2.11 Billion Buyout Offer, from 8 hours ago by Dow Jones

  8 hours ago by Dow Jones
  Companies Mentioned: HALO
  
  By Maitane Sardon
  
  Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion).
  

• DJ Halozyme's Financing of Potential Evotec Deal Remains a Question -- Market Talk, from 9 hours ago by Dow Jones

  9 hours ago by Dow Jones
  Companies Mentioned: HALO
  
  0809 GMT - It remains to be seen how Halozyme Therapeutics would fund a potential 2 billion-euro acquisition of German drug developer Evotec, RBC Capital Markets' analysts say in a research note. San Diego-based biopharmaceutical company Halozyme confirmed Thursday it submitted an all-cash bid of 11 euros a share for Evotec. The move means both industry and private-equity players have shown interest in Evotec. Private-equity firm Triton recently built a stake of about 10% in Evotec. This suggests Evotec's shares are depressed, but that there is significant value within the business that can be unlocked, RBC says. Shares in Evotec jump 22% to 10.56 euros. (adria.calatayud@wsj.com)